A study with a selective intestinal FXR inhibitor, Gly-MCA, demonstrated a reduction of triglyceride accumulation in the liver, decreased blood glucose levels and increased insulin sensitivity in the murine model of obesity (Gonzalez et al., 2016). The gene discussed is NR1H4; the disease is obesity disorder.